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gorithm and collecting costs based on the UK-specific
data. The percent of successfully treated patients was de-
rived from the clinical efficacy adjusted by the annual
persistency. RESULTS: The average total cost per patient
for twelve months of treatment for oxybutynin is £226
and £502 for tolterodine. The percent of successfully
treated patients after one year is 9.5% for oxybutynin
and 36.4% for tolterodine. The average cost-effective-
ness, expressed as cost per successfully treated patient, is
£2377 for oxybutynin and £1395 for tolterodine. CON-
CLUSION: Although the efficacy of oxybutynin and
tolterodine has been measured as equal, the persistency is
over three times higher with tolterodine. While the cost
of therapy for tolterodine is higher than oxybutynin, the
cost-effectiveness of tolterodine is superior. These results
were similar to the US-based model, but driven by the
different treatment approach to OAB in the UK.
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OBJECTIVES: To examine predictors of the decision to
use medication to treat patients newly diagnosed with
overactive bladder (OAB). METHODS: We conducted
an observational study in 217 patients newly diagnosed
with overactive bladder (OAB) enrolled by 32 physicians
nationwide (the ALZA Overactive Bladder Registry). In-
formation was collected on patient demographics, OAB
symptoms, quality of life and type of treatment recom-
mended—medication or behavioral. Treatment with medi-
cation was modeled in a stepwise logistic regression in
which patient age, sex, education level, race/ethnicity,
previous treatment, insurance status, duration of OAB
symptoms, frequency of urination, nocturia, number of
leakage accidents, physician severity rating, and symp-
tom bother were predictors. RESULTS: Participants were
on average 60.7 years old (S.D.  16.7), 82.4% female,
72.7% White, and had experienced OAB symptoms for
8.4 years (S.D.  12.0). They averaged 11 urinations per
day (S.D.  4.2), 2.7 at night (S.D.  1.6), and 1.9 acci-
dents a day (S.D.  3.0) with a mean bother score of 1.9
(S.D.  0.8), indicating “slight” bother. Significant pre-
dictors for treatment with medication were White race
(O.R.  4.6, 95% CI 1.9–11.4), number of accidents
(O.R.  1.2, 95% CI 1.0–1.5), physician OAB severity
ratings, both moderate (O.R.  3.3, 95% CI 1.4–8.0)
and severe (O.R.  3.8, 95% CI 1.0–14.6), college edu-
cation (O.R.  0.4, 95% CI 0.2–0.8), and prior use of
medication(s) (O.R.  3.2, 95% CI 1.2–9.0). Univariate
analyses indicated that Whites and Blacks received pre-
scriptions for OAB at comparable rates, while Asian and
Hispanic patients were much less likely to be prescribed
medication. CONCLUSIONS: Both demographic and
clinical variables are important predictors of the decision
to prescribe medication for overactive bladder. Among
clinical variables, only leakage accidents were associated
with the decision to prescribe medication.
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OBJECTIVE: To collect data on symptoms of bladder
dysfunction in a large German population sample of pa-
tients visiting primary care doctors, urologists or gyne-
cologists for any medical reason. METHODS: During a
total study period of approximately four months, a total
of 2,662 practices of primary care physicians, urologists
and gynecologists asked their visiting patients to fill out a
simple questionnaire consisting of four questions related
to symptoms of bladder dysfunction. The physicians were
asked to discuss the answers with their patients during
the same visit and to make a diagnosis. Based upon the
diagnosis, they were asked whether pharmacotherapy
would be initiated or the patient would be referred to a
specialist. RESULTS: Data of 198,230 patients were avail-
able for analysis. Overall, 22.4% reported symptoms at-
tributable to mixed and 8% to stress incontinence;
43.7% had no symptoms of bladder dysfunction. The
prevalence of symptoms attributable to overactive blad-
der was 25.9%, with the most commonly reported symp-
toms being frequency (41.9%), followed by urgency
(24.3%) and urge incontinence (20.2%). Doctor’s aware-
ness of symptoms was rather poor. Drugs for the treat-
ment of the symptoms of the overactive bladder were
prescribed by about 80% of the urologists; however,
only 40 to 45% of the gynecologists and the primary care
doctors considered this option. CONCLUSION: Consid-
ering the high prevalence of lower urinary tract symp-
toms in a growing elderly population and the impact on
the individual quality of life as well as the social system,
further educational efforts seem necessary to increase
awareness for this problem in the medical community. 
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OBJECTIVE: To estimate C/E and C/U of INFbeta-1b 8
MIU every second day in RRMS in comparison to pla-
cebo. METHODS: The model for the Polish health care
context was developed, based on the use of clinical data
from literature and local data on health care resource uti-
lization and unit cost. The current trial evidence suggests
a significant effect only on the number of relapses, there-
fore a very simple model was constructed, which calcu-
lated cost savings and QALY gains from reductions in
the number of relapses. Only direct medical costs were
analyzed. The perspective of health care payers, time ho-
rizon of two years and discount rate 5% were used. The
primary clinical outcomes were: for CEA, the avoided re-
lapses, and for CUA, QALY. Utility values were obtained
from EQ-5D survey, reported in the randomized trial, or
calculated, making many assumptions based on clinical
opinion, using the Index of Health-Related Quality of
Life. RESULTS: INFbeta-1b decreased the number of re-
lapses by 86/100 patients/2 years. The estimated increase
in QALY per relapse avoided was 0.072 (EQ-5D) or 0.073–
0.082, depending on the severity of relapses (IHRQL). The
QALYs gained by INFbeta-1b over 2 years were estimated
at 6.2 (EQ-5D) or 0.95-7 (IHRQL) for 100 patients. Over
2 years the costs for 100 patients in INFbeta-1b group
were by 14 548 277 PLN higher than in placebo (1 USD 
4.5 PLN). Cost per relapse avoided was 173504 PLN.
Cost per QALYs gained was 2 406 663 PLN or 2 131
616-15 706 642 PLN respectively for EQ-5D and IHRQL
estimation of utility. Sensitivity analysis showed, that C/
U ratio might have an acceptable value (60 000 PLN/
QALY), if the cost of INFbeta-1b decreased by 95% or
the number of QALYs gained increased 40-fold. CON-
CLUSIONS: The high C/U ratio was driven by the cost of
INFbeta-1b and the modest clinical effect.
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OBJECTIVE: Develop a conjoint questionnaire to evalu-
ate patient preferences regarding side effects from anti-
epileptic medications. METHODS: We performed an ex-
tensive literature review and consulted with experts to
identify the constructs of interest. We conducted two
rounds of cognitive interviews with epilepsy patients to
pretest the questionnaire. Between the two sets of inter-
views, the questionnaire was revised to address issues
identified during the first interviews and to incorporate
further advice from a physician specializing in epilepsy.
The second set of interviews was undertaken to assess the
efficacy of the questionnaire modifications. RESULTS:
The combination of these survey design methods greatly
facilitated the development of the conjoint questionnaire
(now ready for use in a full-scale field test). The involve-
ment of patients with epilepsy in the cognitive pretest
provided valuable insights that the literature review and
physician consultations failed to identify. Potential prob-
lems identified and addressed related to the background
questions, the choice of side effects and the descriptions
of the side effects. For example, some of the original side
effects were not particularly familiar or salient to pa-
tients, and were subsequently replaced by alternatives
identified by epilepsy patients interviews and the physi-
cian in his experience with epilepsy patients as more im-
portant. Unexpectedly, we found that respondents fo-
cused first on the potential for driving restrictions when
ranking potential medications. The other side effects were
used only to distinguish between alternatives that did not
differ in their potential for driving restrictions. CON-
CLUSIONS: Although they tend to be under-utilized
within the pharmaceutical industry, cognitive methods
are extremely important tools for examining the thought
processes that affect the quality of answers provided to
questionnaire items. The qualitative information gath-
ered in the patient pretests was a necessary element of the
conjoint instrument design, and helped us to maximize
the comprehensibility and psychometric soundness of the
final questionnaire.
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OBJECTIVE: To determine the utility of a model using
prescription directions versus administrative data to esti-
mate cost savings of a 2:1 gabapentin capsule-to-tablet
interchange protocol from the perspective of an outpa-
tient prescription formulary decision-maker. METHODS:
Database analyses were based on 1852 outpatient pre-
scriptions (712 new, 1140 refills) for gabapentin 300 and
400 mg capsules dispensed at the McGuire Veterans Af-
fairs Medical Center between 5/1/99–4/30/00. A model
was constructed to identify all clinically appropriate con-
vertible prescriptions to yield annual convertible doses.
Over 256 unique prescription directions were analyzed
and assigned to one of 26 prescribing groups. All 1853
prescriptions were then assigned to one of 5 categories (4
non-convertible and 1 convertible category) based on
these groups. Analysis of administrative data identified
2:1 convertible prescriptions if division of quantity dis-
pensed by days supply fields yielded even whole numbers.
A second, conservative approach assumed three times
daily dosing regimens (manufacturer’s recommended guide-
lines) to identify 2:1 conversions. Cost savings were cal-
culated using $0.11 and $0.14 (U.S.) saved per each in-
